AAAAAA
Results: 1-25/32
Authors:
Hallek, M
Schmitt, B
Emmerich, B
Stein, H
Citation: M. Hallek et al., Chronic lymphocytic leukemia - Part 1: Diagnosis, DEUT MED WO, 126(23), 2001, pp. 687-689
Authors:
Hallek, M
Schmitt, B
Emmerich, B
Stein, H
Citation: M. Hallek et al., Chronic lymphocytic leukemia - Part 2: Treatment, DEUT MED WO, 126(23), 2001, pp. 690-695
Authors:
Nicklin, SA
Buening, H
Dishart, KL
de Alwis, M
Girod, A
Hacker, U
Thrasher, AJ
Ali, RR
Hallek, M
Baker, AH
Citation: Sa. Nicklin et al., Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells, MOL THER, 4(3), 2001, pp. 174-181
Authors:
Hacker, UT
Gerner, FM
Buning, H
Hutter, M
Reichenspurner, H
Stangl, M
Hallek, M
Citation: Ut. Hacker et al., Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors, GENE THER, 8(12), 2001, pp. 966-968
Authors:
Wendtner, CM
Schmitt, B
Bergmann, M
Rohnisch, T
Buhmann, R
Hallek, M
Citation: Cm. Wendtner et al., New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia, INT J HEMAT, 73(1), 2001, pp. 32-38
Authors:
Braun-Falco, M
Hallek, M
Citation: M. Braun-falco et M. Hallek, Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response, ARCH DERM R, 293(1-2), 2001, pp. 12-17
Authors:
Schaeffer, M
Schneiderbauer, M
Weidler, S
Tavares, R
Warmuth, M
de Vos, G
Hallek, M
Citation: M. Schaeffer et al., Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases, MOL CELL B, 21(23), 2001, pp. 8068-8081
Authors:
Seisenberger, G
Ried, MU
Endress, T
Buning, H
Hallek, M
Brauchle, C
Citation: G. Seisenberger et al., Real-time single-molecule imaging of the infection pathway of an adeno-associated virus, SCIENCE, 294(5548), 2001, pp. 1929-1932
Authors:
Hallek, M
Buening, H
Ried, M
Hacker, U
Kurzeder, C
Wendtner, CM
Citation: M. Hallek et al., Principles of gene therapy - Issues and status of development, INTERNIST, 42(10), 2001, pp. 1306
Authors:
Hallek, M
Schmitt, B
Wilhelm, M
Busch, R
Krober, A
Fostitsch, HP
Sezer, O
Herold, M
Knauf, W
Wendtner, CM
Kuse, R
Freund, M
Franke, A
Schriever, F
Nerl, C
Dohner, H
Thiel, E
Hiddemann, W
Brittinger, G
Emmerich, B
Citation: M. Hallek et al., Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL): results of a phase II study of the German CLL Study Group, BR J HAEM, 114(2), 2001, pp. 342-348
Authors:
Kunzmann, V
Ruediger, T
Hallek, M
Mueller-Hermelink, HK
Wilhelm, M
Citation: V. Kunzmann et al., Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment, BLOOD, 98(6), 2001, pp. 1991-1992
Authors:
Huhn, D
von Schilling, C
Wilhelm, M
Ho, AD
Hallek, M
Kuse, R
Knauf, W
Riedel, U
Hinke, A
Srock, S
Serke, S
Peschel, C
Emmerich, B
Citation: D. Huhn et al., Rituximab therapy of patients with B-cell chronic lymphocytic leukemia, BLOOD, 98(5), 2001, pp. 1326-1331
Authors:
Oetzel, C
Jonuleit, T
Gotz, A
van der Kuip, H
Michels, H
Duyster, J
Hallek, M
Aulitzky, WE
Citation: C. Oetzel et al., The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X, CLIN CANC R, 6(5), 2000, pp. 1958-1968
Authors:
Feuring-Buske, M
Kneba, M
Unterhalt, M
Engert, A
Gramatzki, M
Hiller, E
Trumper, L
Brugger, W
Ostermann, H
Atzpodien, J
Hallek, M
Aulitzky, E
Hiddemann, W
Citation: M. Feuring-buske et al., IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, ANN HEMATOL, 79(9), 2000, pp. 493-500
Authors:
von Bubnoff, N
Adler, S
Danhauser-Riedl, S
Kamp, T
Nerl, C
Emmerich, B
Hallek, M
Citation: N. Von Bubnoff et al., The activation of intracellular tyrosine kinases by interferon-alpha (IFN alpha) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukemia patients, ANN HEMATOL, 79(3), 2000, pp. 119-126
Authors:
Wobus, CE
Hugle-Dorr, B
Girod, A
Petersen, G
Hallek, M
Kleinschmidt, JA
Citation: Ce. Wobus et al., Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection, J VIROLOGY, 74(19), 2000, pp. 9281-9293
Authors:
Nolte, A
Buhmann, R
Emmerich, B
Schendel, D
Hallek, M
Citation: A. Nolte et al., Reconstitution of the cellular immune response after autologous peripheralblood stem cell transplantation in patients with non-Hodgkin's lymphoma, BR J HAEM, 108(2), 2000, pp. 415-423
Authors:
Jonuleit, T
van der Kuip, H
Miething, C
Michels, H
Hallek, M
Duyster, J
Aulitzky, WE
Citation: T. Jonuleit et al., Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines, BLOOD, 96(5), 2000, pp. 1933-1939
Authors:
Girod, A
Ried, M
Wobus, C
Lahm, H
Leike, K
Kleinschmidt, J
Deleage, G
Hallek, M
Citation: A. Girod et al., Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2, NAT MED, 5(9), 1999, pp. 1052-1056
Authors:
Girod, A
Ried, M
Wobus, C
Lahm, H
Leike, K
Kleinschmidt, J
Deleage, G
Hallek, M
Citation: A. Girod et al., Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 (vol 5, pg 1052, 1999), NAT MED, 5(12), 1999, pp. 1438-1438
Authors:
Selmayr, M
Strehl, J
Kremer, JP
Kremmer, E
Doenecke, A
Hallek, M
Menzel, H
Thielemans, K
Thierfelder, S
Mocikat, R
Citation: M. Selmayr et al., Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype, GENE THER, 6(5), 1999, pp. 778-784
Authors:
Braun-Falco, M
Doenecke, A
Smola, H
Hallek, M
Citation: M. Braun-falco et al., Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors, GENE THER, 6(3), 1999, pp. 432-441
Authors:
Emmerich, B
Hallek, M
Citation: B. Emmerich et M. Hallek, Recent advances in the biology and treatment of chronic lymphocytic leukemia and related diseases, J MOL MED-J, 77(2), 1999, pp. 258-258
Authors:
Meinhardt, G
Wendtner, CM
Hallek, M
Citation: G. Meinhardt et al., Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival, J MOL MED-J, 77(2), 1999, pp. 282-293
Authors:
Warmuth, M
Danhauser-Riedl, S
Hallek, M
Citation: M. Warmuth et al., Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies, ANN HEMATOL, 78(2), 1999, pp. 49-64